COMP <GO>
BRVE vs TRVI // ENTERPRISE SCALE & MARKET CAP
Braveheart Bio Inc. (NASDAQ) VS. Trevi Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BRVE 0
— TRVI 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TRVI
LAST: $21.19 (-2.62%) • MKT CAP: $1.91B
market-cap
$1.91B
LAST: $13.81 (+2.15%) • MKT CAP: $1.97B
market-cap
$1.97B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRVE VS. TRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRVE | TRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -23.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.14% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 50.7 | -1.47 | TRVI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.91B | $1.97B | -$59.7M | TRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRVE REV | TRVI REV | BRVE GROSS % | TRVI GROSS % | BRVE FCF | TRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$42.1M |
| FY 2024 | — | $0 | — | — | — | -$38.3M |
| FY 2023 | — | $0 | — | — | — | -$31.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRVE // BETA —
TRVI // BETA —